Rein Therapeutics (RNTX) Competitors $1.19 0.00 (0.00%) As of 11:27 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RNTX vs. SPRO, ZNTL, VTGN, ANRO, ATOS, ADAG, TCRX, HLVX, MEIP, and SAVAShould you be buying Rein Therapeutics stock or one of its competitors? The main competitors of Rein Therapeutics include Spero Therapeutics (SPRO), Zentalis Pharmaceuticals (ZNTL), VistaGen Therapeutics (VTGN), Alto Neuroscience (ANRO), Atossa Genetics (ATOS), Adagene (ADAG), TScan Therapeutics (TCRX), HilleVax (HLVX), MEI Pharma (MEIP), and Cassava Sciences (SAVA). These companies are all part of the "pharmaceutical products" industry. Rein Therapeutics vs. Its Competitors Spero Therapeutics Zentalis Pharmaceuticals VistaGen Therapeutics Alto Neuroscience Atossa Genetics Adagene TScan Therapeutics HilleVax MEI Pharma Cassava Sciences Spero Therapeutics (NASDAQ:SPRO) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment. Which has better valuation & earnings, SPRO or RNTX? Rein Therapeutics has lower revenue, but higher earnings than Spero Therapeutics. Spero Therapeutics is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpero Therapeutics$34.09M3.24-$68.57M-$0.98-2.00Rein TherapeuticsN/AN/A-$62.88M-$2.69-0.44 Do insiders and institutionals have more ownership in SPRO or RNTX? 25.6% of Spero Therapeutics shares are held by institutional investors. Comparatively, 90.9% of Rein Therapeutics shares are held by institutional investors. 5.5% of Spero Therapeutics shares are held by insiders. Comparatively, 5.1% of Rein Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media favor SPRO or RNTX? In the previous week, Rein Therapeutics had 12 more articles in the media than Spero Therapeutics. MarketBeat recorded 13 mentions for Rein Therapeutics and 1 mentions for Spero Therapeutics. Spero Therapeutics' average media sentiment score of 1.91 beat Rein Therapeutics' score of 0.80 indicating that Spero Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Spero Therapeutics Very Positive Rein Therapeutics Positive Is SPRO or RNTX more profitable? Rein Therapeutics has a net margin of 0.00% compared to Spero Therapeutics' net margin of -110.35%. Spero Therapeutics' return on equity of -120.27% beat Rein Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Spero Therapeutics-110.35% -120.27% -55.61% Rein Therapeutics N/A -141.11%-33.83% Do analysts rate SPRO or RNTX? Spero Therapeutics presently has a consensus price target of $5.00, suggesting a potential upside of 155.10%. Rein Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 740.34%. Given Rein Therapeutics' higher possible upside, analysts clearly believe Rein Therapeutics is more favorable than Spero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spero Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Rein Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more volatility & risk, SPRO or RNTX? Spero Therapeutics has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500. Comparatively, Rein Therapeutics has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. SummarySpero Therapeutics and Rein Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Get Rein Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNTX vs. The Competition Export to ExcelMetricRein TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.74M$3.09B$5.66B$10.31BDividend YieldN/A2.36%5.68%4.61%P/E Ratio-0.4420.6576.0726.32Price / SalesN/A401.90515.05169.28Price / Cash2.5045.9137.5661.52Price / Book2.779.7413.046.34Net Income-$62.88M-$52.73M$3.29B$270.94M7 Day Performance3.48%1.18%0.06%0.28%1 Month Performance0.85%6.85%4.21%6.87%1 Year PerformanceN/A19.37%69.54%29.24% Rein Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNTXRein Therapeutics2.5346 of 5 stars$1.19flat$10.00+740.3%N/A$27.74MN/A-0.449News CoverageAnalyst ForecastAnalyst RevisionSPROSpero Therapeutics3.9469 of 5 stars$1.90-2.6%$5.00+163.2%+53.9%$109.74M$34.09M-1.94150Positive NewsZNTLZentalis Pharmaceuticals1.8583 of 5 stars$1.49-4.5%$8.20+450.3%-62.2%$107.48M$26.87M-0.66160News CoveragePositive NewsVTGNVistaGen Therapeutics0.6353 of 5 stars$3.39-3.1%N/A+15.3%$107.38M$490K-1.9040Gap DownANROAlto Neuroscience2.4418 of 5 stars$3.88-1.2%$8.50+119.0%-67.4%$106.41MN/A-1.62N/AATOSAtossa Genetics2.5036 of 5 stars$0.84+2.0%$6.17+634.3%-41.0%$106.33MN/A-3.658Analyst ForecastADAGAdagene2.5313 of 5 stars$2.24-4.3%$7.00+212.5%-9.0%$105.57M$103.20K0.00260TCRXTScan Therapeutics3.1415 of 5 stars$1.76-4.9%$7.80+343.2%-63.9%$104.98M$2.82M-1.61100Positive NewsHLVXHilleVax1.4975 of 5 stars$2.09flat$2.00-4.3%N/A$104.79MN/A-1.4620MEIPMEI Pharma1.036 of 5 stars$3.19+14.7%N/A+8.1%$104.72MN/A-0.67100Gap UpHigh Trading VolumeSAVACassava Sciences2.7954 of 5 stars$2.11-2.3%$2.00-5.2%-89.0%$104.35MN/A-0.8330News CoveragePositive NewsInsider TradeOptions VolumeGap Down Related Companies and Tools Related Companies SPRO Competitors ZNTL Competitors VTGN Competitors ANRO Competitors ATOS Competitors ADAG Competitors TCRX Competitors HLVX Competitors MEIP Competitors SAVA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNTX) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rein Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rein Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
